BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32950590)

  • 1. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
    Leuschner M; Maier KP; Schlichting J; Strahl S; Herrmann G; Dahm HH; Ackermann H; Happ J; Leuschner U
    Gastroenterology; 1999 Oct; 117(4):918-25. PubMed ID: 10500075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
    Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
    Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
    Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
    Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
    Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
    Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
    Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
    Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
    Kaplan MM; Bonder A; Ruthazer R; Bonis PA
    Dig Dis Sci; 2010 Nov; 55(11):3207-17. PubMed ID: 20559727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.
    Ma H; Zeng M; Han Y; Yan H; Tang H; Sheng J; Hu H; Cheng L; Xie Q; Zhu Y; Chen G; Gao Z; Xie W; Wang J; Wu S; Wang G; Miao X; Fu X; Duan L; Xu J; Wei L; Shi G; Chen C; Chen M; Ning Q; Yao C; Jia J
    Medicine (Baltimore); 2016 Nov; 95(47):e5391. PubMed ID: 27893675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis.
    Neuman MG; Cameron RG; Haber JA; Katz GG; Blendis LM
    Liver; 2002 Jun; 22(3):235-44. PubMed ID: 12100574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.
    Zhang H; Yang J; Zhu R; Zheng Y; Zhou Y; Dai W; Wang F; Chen K; Li J; Wang C; Li S; Liu T; Abudumijiti H; Zhou Z; Wang J; Lu W; Wang J; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():567-74. PubMed ID: 25632224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.